| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(+/-)-Methotrimeprazine D6 targets dopamine D3 receptor and histamine H1 receptor as an antagonist. It also exhibits affinity for other central nervous system receptors including dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors, contributing to its broad pharmacological profile. The compound acts primarily as a D3 dopamine receptor antagonist with additional antihistaminergic properties. As a deuterated internal standard, it competes with the parent compound for these receptor binding sites but is used analytically rather than therapeutically. The isotopic labeling does not significantly alter the receptor binding characteristics compared to the non-deuterated form.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Methotrimeprazine (the non-deuterated parent) exhibits antagonist activity at dopamine D3 receptors and histamine H1 receptors. The compound shows potent binding affinity to these targets with nanomolar IC50 values typical of phenothiazine antipsychotics. In receptor binding assays, Methotrimeprazine displaces radiolabeled ligands from D3 and H1 receptors in a concentration-dependent manner. The deuterated analog (D6) is expected to exhibit comparable in vitro binding characteristics to the parent compound, as isotopic substitution generally does not substantially affect receptor-ligand interactions. The compound also demonstrates activity at other CNS receptors including D2, 5-HT2A, and alpha-1 adrenergic sites.
|
| ln Vivo |
In vivo, Methotrimeprazine (parent compound) acts as a centrally active antipsychotic and analgesic agent following systemic administration. The compound penetrates the blood-brain barrier due to its lipophilic phenothiazine structure, producing sedative, antipsychotic, and antiemetic effects. It has been used clinically as an antipsychotic medication and as an adjuvant analgesic. The (R)-isomer of Methotrimeprazine demonstrates analgesic activity, while the racemic mixture exhibits broader CNS effects. The deuterated form (D6) is not intended for in vivo pharmacological studies but rather serves as an analytical standard for quantifying parent drug levels in preclinical and clinical samples using mass spectrometry-based methods.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Methotrimeprazine typically involve competition binding experiments using membrane preparations from cells expressing recombinant human dopamine D3 or histamine H1 receptors. Radiolabeled ligands such as [3H]-spiperone (for D3) or [3H]-pyrilamine (for H1) are incubated with varying concentrations of the test compound in assay buffer. After incubation at room temperature or 37degC for 1-2 hours, bound and free radioligands are separated by rapid filtration through glass fiber filters or by centrifugation. Filter-bound radioactivity is quantified by liquid scintillation counting. IC50 values are determined by nonlinear regression analysis of competition curves, and Ki values are calculated using the Cheng-Prusoff equation. Non-specific binding is determined in the presence of excess unlabeled ligand.
|
| Cell Assay |
In vitro cellular assays for Methotrimeprazine involve functional readouts in cell lines engineered to express dopamine D3 or histamine H1 receptors coupled to appropriate signaling pathways. For D3 receptor studies, cells expressing the receptor and a G protein-coupled inwardly rectifying potassium channel or cAMP response element reporter are used. Cells are seeded in multi-well plates and treated with serial dilutions of the compound. Intracellular cAMP levels are measured using ELISA or HTRF-based detection kits following agonist stimulation. For H1 receptor assays, calcium mobilization or beta-arrestin recruitment assays are employed. IC50 values for antagonist activity are calculated from dose-response curves using four-parameter logistic regression. The deuterated D6 analog is typically used as an internal standard in cell-based assays rather than as a test compound.
|
| Animal Protocol |
In vivo animal studies for Methotrimeprazine have been conducted in rodent models to evaluate antipsychotic and analgesic efficacy. Typical protocols involve administration of the compound via intraperitoneal, subcutaneous, or oral routes at doses ranging from 1-10 mg/kg. Behavioral tests such as the conditioned avoidance response, catalepsy test, and hot plate or tail-flick analgesia tests are performed to assess antipsychotic and analgesic activities. For pharmacokinetic studies, the deuterated D6 form is administered as an internal standard alongside the parent compound. Blood and tissue samples are collected at predetermined time points, processed, and analyzed by LC-MS/MS to quantify drug concentrations and calculate pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
(+/-)-Methotrimeprazine D6 is used as an analytical internal standard rather than a therapeutic agent, so comprehensive pharmacokinetic data for the deuterated form are limited. The parent compound Methotrimeprazine (Levomepromazine) is orally bioavailable with extensive first-pass metabolism. It undergoes hepatic metabolism primarily via CYP450 enzymes, including CYP2D6 and CYP3A4, producing active and inactive metabolites. The elimination half-life ranges from 15-30 hours. The deuterated D6 analog exhibits nearly identical physicochemical properties to the parent compound, including similar lipophilicity (logP ~4.5), protein binding (~90%), and metabolic stability, making it suitable as an internal standard for bioanalysis. The compound is soluble in organic solvents such as methanol, DMSO, and acetonitrile.
|
| Toxicity/Toxicokinetics |
Toxicological information for (+/-)-Methotrimeprazine D6 is primarily extrapolated from the parent compound Methotrimeprazine. The parent compound is a phenothiazine antipsychotic with known adverse effects including sedation, orthostatic hypotension, anticholinergic effects (dry mouth, constipation), and extrapyramidal symptoms. Overdose can cause CNS depression, hypotension, and cardiac arrhythmias. The compound is classified for research use only and is not intended for human therapeutic or diagnostic applications. Standard laboratory precautions should be observed when handling this compound, including the use of appropriate personal protective equipment and working in a well-ventilated fume hood. Long-term storage is recommended in a cool, dry place at -20degC, protected from light.
|
| Additional Infomation |
(+/-)-Methotrimeprazine D6 (CAS#: 1189805-51-3) is a deuterium-labeled internal standard for Methotrimeprazine (Levomepromazine), a phenothiazine neuroleptic with antipsychotic and analgesic properties. The molecular formula is C1₉H24D₆N2OS with a molecular weight of 334.51. The compound contains six deuterium atoms replacing the two N-methyl groups, providing a mass shift of +6 Da for mass spectrometry detection. This isotopic analog is widely used in LC-MS/MS bioanalytical methods for therapeutic drug monitoring, pharmacokinetic studies, and forensic toxicology. Methotrimeprazine is clinically used in some countries as an antipsychotic and antiemetic. As of the current date, the deuterated D6 form is a research-grade analytical standard and is not approved for therapeutic use.
|
| Molecular Formula |
C19H24N2OS
|
|---|---|
| Molecular Weight |
334.508633613586
|
| Exact Mass |
334.198
|
| CAS # |
1189805-51-3
|
| Related CAS # |
(±)-Levomepromazine;851-68-3;(Rac)-Levomepromazine-d3 hydrochloride;1216745-60-6
|
| PubChem CID |
45039713
|
| Appearance |
White to yellow solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
378
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C2C=CC=CC=2N(C2C=C(C=CC1=2)OC)CC(C)CN(C([2H])([2H])[2H])C([2H])([2H])[2H]
|
| InChi Key |
VRQVVMDWGGWHTJ-XERRXZQWSA-N
|
| InChi Code |
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/i2D3,3D3
|
| Chemical Name |
3-(2-methoxyphenothiazin-10-yl)-2-methyl-N,N-bis(trideuteriomethyl)propan-1-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9894 mL | 14.9472 mL | 29.8945 mL | |
| 5 mM | 0.5979 mL | 2.9894 mL | 5.9789 mL | |
| 10 mM | 0.2989 mL | 1.4947 mL | 2.9894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
